---
title: "Aquestive Therapeutics (AQST) Receives a Buy from Oppenheimer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286564550.md"
description: "Oppenheimer analyst Andreas Argyrides has reiterated a Buy rating on Aquestive Therapeutics (AQST) with a price target of $8.00. The analyst consensus for the company is a Strong Buy, with an average price target of $8.75. Argyrides has an average return of 10.3% and a 45.76% success rate on his stock recommendations."
datetime: "2026-05-15T12:01:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286564550.md)
  - [en](https://longbridge.com/en/news/286564550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286564550.md)
---

# Aquestive Therapeutics (AQST) Receives a Buy from Oppenheimer

Oppenheimer analyst Andreas Argyrides reiterated a Buy rating on Aquestive Therapeutics today and set a price target of $8.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Argyrides covers the Healthcare sector, focusing on stocks such as United Therapeutics, Aquestive Therapeutics, and MannKind. According to TipRanks, Argyrides has an average return of 10.3% and a 45.76% success rate on recommended stocks.

Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $8.75.

### Related Stocks

- [AQST.US](https://longbridge.com/en/quote/AQST.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)
- [MNKD.US](https://longbridge.com/en/quote/MNKD.US.md)

## Related News & Research

- [Aquestive Secures New Oaktree Term Loan to Fund Anaphylm](https://longbridge.com/en/news/286317797.md)
- [Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree | AQST Stock News](https://longbridge.com/en/news/286110447.md)
- [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md)
- [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md)
- [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md)